Hepcidin reduction in liver cancers correlated with risk factors like non-alcoholic fatty liver disease (NAFLD) and liver fibrosis, as well as cancer grade and tumor stage. Here, HAMP is linked to metabolic dysfunction-associated steatotic liver disease.